Palliative Care Symptom Guide July 2013 Table of Contents General Principles of Pain Management. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 Select Opiate Products. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 Equianalgesic Dosing (Opioid conversion). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 Patient Controlled Analgesia (PCA). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 Opioid Dosing in Renal or Hepatic Dysfunction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 Guidelines for Naloxone Administration and Patient Monitoring. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 Insomnia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7-8 Nausea and Vomiting. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9-10 Constipation and Bowel Protocol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11-12 Delirium Diagnosis (CAM-ICU and the ICDSC). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13-14 Delirium: Treatment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15-16 Depression: Screening Tools and Treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17-19 End of Life Care: Symptom Management Treatment of Dyspnea and Pain at the End of Life . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 Oral Secretions at the End of Life. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21 Palliative Care and Pain Resources. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22 Acknowledgements. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23 1 Pain Scale 0 1 2 3 4 5 6 7 8 No Pain None = 0; Mild = 2.5; Moderate = 5; Severe = 7.5; Excruciating = 10 9 10 Worst Pain Imaginable General Principles of Pain Management 1. Assess pain using a standardized pain scale. Pain is a subjective feeling: ask the patient using the above 0-10 scale. If the patient is cognitively impaired, use the Abbey pain scale. (See page 2.) Frequency of assessment: at the time of the initial interview, every eight hours, and PRN (at least every two hours when pain is severe). 6. Determine the route the opiate will be given. 2. In opiate naive patients, start with short-acting opioids (morphine, hydromorphone, and oxycodone) to control acute, moderate to severe pain. a.IM should never be given. Never use long-acting opioids to control acute pain. 7. Determine the dosing schedule. 3.When titrating or changing opiate dose, start by calculating the a.For non-opiate naive patients, use long-acting pain medicine for ongoing pain, not previous day’s Oral Morphine Equivalent (OME). prn; for opiate naive patients use only prn until you have a sense of how much a.Since all potent opioids produce analgesia by the same mechanism, they medicine the patient needs. will produce the same degree of analgesia if provided in equianalgesic b.Give 66-75% of patient’s stable daily OME as long acting. doses (see equanalgesic table). c.Consider a pca if the pain requirements are rapidly increasing or unknown. b.Rectal=oral 8. Determine break through dose (for acute pain in patient with otherwise c.SQ=IM=IV controlled pain). 4.Determine if the dose is adequate for the pain and dose adjust. a.Use the same opiate for short- and long-acting pain when possible. a.Titrate at least every 24 hours when the pain is moderate and as often as every b.5-15% of total daily long acting opiate dose every 3 hr prn. four hours when using IV opioids and the pain is severe. 9. Manage opiate side effects. Constipation must be treated prophylactically b. Increase dose 25-50% for moderate pain and 50-100% for severe pain. (see page 6). 5. Determine the opiate that will be used and dose adjust for incomplete 10. Determine whether co-analgesics would help. cross tolerance. a.The only reason to change from one opiate to another is side effects or renal failure. b.When rotating opiate, decrease the dose 25-50% to correct for incomplete cross tolerance. 1 PHARMACISTS WILL NOT MAKE SUBSTITUTIONS OR CORRECTIONS FOR OPIATES. IF SCRIPTS ARE NOT WRITTEN EXACTLY (e.g., CORRECT DRUG, DOSE, AND SCHEDULE), THEY WILL NOT BE FILLED. SELECT NON-INJECTABLE OPIOID PRODUCTS Drug Short Acting (mg) Long Acting (mg) Morphine Tabs (15, 30 mg) Caps (15, 30 mg) MS Contin Tabs (q12hr) (15, 30, 60, 100, 200 mg) MSIR Oral Solution (10 mg/5 mL, 20 mg/5 mL) Oramorph SR Tabs (q12hr) (15, 30, 60, 100 mg) MSIR, Roxanol Oral Concentrate (100 mg/5mL) (1)Kadian Caps (q12hr or q24hr) (10, 20, 30, 40, 50, 60, 70, 80, 100, 130, 150,200mg) (2, 5) Supp (5, 10, 20, 30 mg) Avinza Caps (q24hr) (30, 60, 90, 120 mg) (2, 5) OxycodoneRoxicodone Tabs (5, 15, 30 mg) OxyIR Caps (5 mg) OxyContin Tabs (q12hr) (10, 15, 20, 30, 40, 60, 80 mg) Roxicodone Oral Solution (5 mg/5 mL) OxyFAST, Oxydose, Roxicodone Intensol Oral Concentrate (20 mg/mL) (1,6) Hydromorphone Dilaudid Tabs (2, 4, 8 mg) (8 mg brand-name scored) Exalgo Tabs (q24h) (8, 12, 16, 32 mg) (Dilaudid)Dilaudid Oral Solution (5 mg/5 mL) Supp (3 mg) Codeine Tabs (15, 30, 60 mg) Solution or Elixir (15 mg/5 mL) Fentanyl See note (7)Duragesic Transdermal Patch (12.5, 25, 50, 75, 100 mcg/hr) Oxymorphone Opana (5, 10 mg) Opana ER (5, 7.5, 10, 15, 20, 30, 40 mg) SELECT COMBINATION OPIOID PRODUCTS Drug Formulation/Strength (mg/mg) (8) Anexsia (hydrocodone/acetaminophen) (4,6) Empirin with Codeine (codeine/aspirin) (4,6) Lorcet (hydrocodone/acetaminophen) (3,4) Lortab (hydrocodone/acetaminophen) (3,4) Norco (Hydrocodone/acetaminophen) (3,4) Percocet (oxycodone/acetaminophen) (3,4) Percodan (oxycodone/aspirin) (4) Roxicet (oxycodone/acetaminophen) (4) Tylenol with Codeine (codeine/acetaminophen) (3) Vicodin (hydrocodone/acetaminophen) (3,4) Vicoprofen (hydrocodone/ibuprofen) (6) Zydone (hydrocodone/acetaminophen) (4,6) Tabs 5/325 (scored), 5/500 (scored), 7.5/325, 7.5/650 (scored), 10/660 (scored) Tabs 30/325 (#3), 60/325 (#4) Tabs 7.5/650 (scored), 10/650 (scored) Caps 5/500 Tabs 2.5/500, 5/500 (scored), 7.5/500 (scored), 10/500 Elixir 7.5/500 per 15 mL Tabs 5/325, 7.5/325, 10/325 Tabs 2.5/325, 5/325, 7.5/325, 7.5/500, 10/325, 10/650 Tabs 5/325 Tabs 5/325 Caps 5/500 Oral Solution 5/325 per 5 mL Tabs 15/300 (#2), 30/300 (#3), 60/300 (#4) Oral Solution 12/120 per 5 mL Tabs 5/300, 7.5/300 (ES), 10/300 (HP) Tabs 7.5/200 Tabs 5/400, 7.5/400, 10/400 (1) Orders for concentrated oral opioid solutions must include drug name and strength (e.g. 100 mg/5mL) to avoid confusion with other oral solutions. (2) Data supporting safe use with enteral feeding tubes (must use size 16 French or larger). See Kadian prescribing information and UPMC PUH SHY online formulary (Avinza) for product-specific instructions. (3) Maximum daily dose of acetaminophen is 4 grams in patients with normal liver function. (4) Many other brand name products contain similar combinations of opioids. (5) Formulary restricted. (6) Non-formulary. (7)Prescribers must complete Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) (8) As of Fall 2008, all combination opiates with more than 325 mg of acetaminophen will be non-formulary. 2 Oral and Parenteral Opioid Analgesic Equivalencies and Relative Potency of Opioids as Compared with Morphine* When converting from one opioid to another, you should use 50–75% of the equivalent dose. Allow for incomplete cross-tolerance between different opioids (may need to titrate up rapidly and use PRN dose to ensure effective analgesia for the first 24 hours). Avoid IM injections because of inconsistent absorption and patient discomfort. Opioid Agonists Parenteral mg (2) Oral mg (3) Duration of Effect Morphine 10 30 3–4 hours Oxycodone 20–30 3–4 hours Hydromorphone 1.5 7.5 3–4 hours Meperidine (1) (not recommended) 75 300 3 hours Fentanyl (4) 0.1** 1–2 hours Codeine 130 200 3–4 hours Hydrocodone 25–30 Oxymorphone 1 10 3–6 hours *These are rough approximations; individual patients may vary. ** Equivalency for a one time dose of IV Fentanyl only. For Fentanyl patch conversion, see box below. 1) Meperidine is not a first-line opioid. Avoid in patients with renal dysfunction. Contraindicated with MAOIs. Please see UPMC Meperidine Guidelines before prescribing. TWENTY-FOUR HOUR ORAL MORPHINE EQUIVALENT DIVIDED BY 2 IS EQUAL 2) Parenteral opioid: onset of action, 5 minutes; peak, 15 min. TO FENTANYL PATCH DOSE IN MCG/HR. 3) Oral opioid: onset of action, 15–30 minutes; peak, 45–60 min. IV fentanyl dose/hr=transdermal fentanyl dose NOTE: PATCH TAKES 12–24 HRS TO ACHIEVE FULL EFFECT. WHEN REMOVING A PATCH, REMEMBER THE ANALGESIC EFFECT CAN STILL LAST 24 HRS. Please refer to APS Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain (2003); American Pain Society (APS) Guideline for the Management of Cancer Pain in Adults and Children (2005). 3 Patient Controlled Analgesia (PCA) Use the preprinted PCA order form for all new PCA orders and dose The following are suggestions for the PCA order for adults. Like all opioid orders, doses must be individualized. changes. EDUCATE FAMILIES NOT TO PRESS THE PCA BUTTON! Loading Starting Patient Lockout One-hour Dose Continuous infusion dose(s) (1) Administered Dose* (2) Interval (3) Limit (optional) (4) rate in mg/hr (5) Morphine (6) Opioid naive: 1 mg 8 –20 min. 7–10 mg 2-4 mg q 15 min Elderly (>70 yrs.) 0.5 mg 8 –20 min. 4– 6 mg When indicated, 2mg q 20 min. calculate based on titrated to pain relief intermittent PCA use Hydromorphone Opioid naive: 0.2 mg 8 –20 min. 0.7–1.4 mg or previous opioid (Dilaudid) 0.2–0.3 mg q 15 min requirement. Elderly (>70 yrs.) Elderly: 0.1 mg 8 –20 min. 0.4–0.6 mg 0.2mg q 20 min titrated to pain relief 4 *Opioid tolerant and chronic/cancer pain patients may require higher doses press the button and be able to comprehend instructions on when to press and continuous infusions. the button. In the elderly, consider a longer lockout interval. 1.PCA alone is a maintenance technique. Patients should receive loading 4.The hour limit should not be less than the available total hourly patient doses (delivered through the infuser) that are titrated to achieve an adequate administered dose. Bolus doses and the continuous infusion are included level of analgesia (pain score less than or equal to 4/10). in the one-hour dose limit count. 2.Quantity delivered when button is pressed. Reduce doses by 30-50% 5.Not recommended for patients who are opioid naive, the elderly, patients in elderly and patients with liver disease. Do not increase dose based with altered mentation, or with Obstructive Sleep Apnea, COPD, or asthma. on increased body weight; this is especially important in patients with 6.Morphine is generally the opioid of choice. Hydromorphone is preferred in Obstructive Sleep Apnea. Dosing depends on the patient—young vs. patients with impaired renal function. elderly/opioid naive vs. tolerant. If pain unrelieved following administration of loading dose(s), increase 3.How frequently demand dose can be activated. Patient must be able to loading dose by 50% and titrate to pain score less than or equal to 4/10. Opioid Dosing in Renal or Hepatic Dysfunction Given the paucity of pharmacokinetic and pharmacodynamic data of opioids in renal failure, it is difficult to advocate for specific analgesic treatment algorithms. However, the following guide has been proposed for the initial dosing of the safer opioids in renal failure. • Creatinine Clearance > 50 mL/min: normal dosing. • Creatining Clearance < 10 mL/min: 50% of normal • Creatinine Clearance of 10-50 mL/min: 75% of normal. General Opioid safety recommendations in renal insufficiency: Opioid name Recommendation Comments Codeine Not recommended Causes profound toxicity which can be delayed and may occur after trivial doses Fentanyl Considered safe Has no active metabolics Hydromorphone Use with caution Considered safe in dialysis patients Meperidine Not recommended Accumulation of normeperidine can cause seizures Methadone Considered safe No active metabolites; has several other precautions Morphine Not recommended Rapid accumulation of nondialyzable metabolites that are neurotoxic, avoid long acting preparations Oxycodone Use with caution Can accumulated resulting in CNS toxicity and sedation Oxymorphone Use with caution May accumulate resulting in respiratory depression and oversedation General Opioid safety recommendations in hepatic insufficiency: Opioid name Recommendation Comments Codeine Not recommended Impaired conversion of codeine to the active compound, morphine, in the liver to be active Pharmacokinetics were not altered in patients with cirrhosis. With continued use, recovery time after termination of Fentanyl Considered safe infusion may be longer Hydromorphone Meperidine Methadone Morphine Use with caution Not recommended Not recommended Use with caution Oxycodone Oxymorphone Use with caution Not recommended Risk of accumulation of parent drug due to decreased conversion to metabolites and decreased elimination. Recommended to decrease dose by 50% of the usual amount. Accumulation of toxic metabolite, normeperidine, may cause CNS toxicity Risk of accumulation with severe liver disease. Recommended to decrease frequency of administration and dosage because of decreased clearance and increased t1/2 and oral bioavailability Risk of accumulation of parent drug due to decreased conversion to metabolites and decreased elimination. Recommended to reduce dose by 1/2 to 1/3 of the usual amount and avoid in severe cirrhosis Contraindicated in moderate to severe liver dysfunction. Recommend 1/2 of the usual dose in mild hepatic impairment References: Arnold RM, Verrico P, and Davison SN. Opioid Use in Renal Failure #161. J Palliat Med. 2007. 10(6):1403. Gina Carbonara, PharmD. Opioids in Patients with Renal or Hepatic Dysfunction. Practical Pain Management Volume 8, Issue 4 5 Guidelines for Naloxone Administration and Patient Monitoring 1. Nurses may administer naloxone without a physician’s order when patients who have received an opioid meet the following criteria: (a) Sedation Scale = 3 (Somnolent; Difficult to arouse), (b) RR < 8 OR Oxygen Saturation < 92% and RR < 12 2. If the criteria listed above are met, stop the administration of the opioid (including fentanyl patches) and benzodiazepines. 3. Provide oxygen via face mask STAT. 4. Method for naloxone administration: Naloxone 0.04 mg IV q 1 minute until a change in alertness is observed. Dilute 0.4mg naloxone (one ampule) with NSS to a total volume of 10ml (1 ml = 0.04 mg) in a 10 ml syringe. 5. Notify the primary physician and/or house staff of the need to immediately evaluate the patient. If the house staff does not arrive within five minutes or if the nurse assesses the need, a “Condition C” should be called. 6 Titrate the prescribed naloxone until the patient is responsive. The half-life of naloxone (ONE HOUR) is shorter than the half-life of opioid agonists. Naloxone administration should not cause pain to return or precipitate opioid withdrawal. If a response is not obtained after one ampule of naloxone (10 cc of diluted solution) is administered, examine the patient for alternate causes of sedation and respiratory depression. For assistance with further naloxone dosing, please contact the Toxicology Treatment Program (412-647-7000). 7. Re-evaluate the events leading to the need for naloxone administration. In cases where the prescribed opioid dosing was too high, reassess the therapeutic plan for pain management. Consider decreasing the opioid dose by 50%. Resume opioid administration when the patient is easily aroused, is beginning to experience pain, and after the RR increases to > 9. 6 Non Pharmacologic and Indirect Measures for Treatment of Insomnia Insomnia is most often secondary and attributable to underlying medical or psychological conditions, medications or other substances that interfere with sleep or poor sleep environment. Non-pharmacologic Components Evidence Good sleep hygiene behaviors Stable bedtimes and rising times, no napping Regular daytime light exposure Quiet dark room at night; no TV while trying to sleep Family should place familiar items in the patient’s room Avoid evening intake of caffeine, nicotine, alcohol, and diuretics Minimize nighttime procedures and noise Minimize administration of steroids, beta blockers, psychostimulants at nighttime Maintain adequate nutrition No heavy exercise/ bright lights before bedtime Encourage a 30 min relaxation period before bedtime Can improve time to onset of sleep and total sleep time Treating underlying disorders and symptoms Use of BIPAP for obstructive sleep apnea Manage pain, dyspnea, nausea and vomiting Look for heart failure, gastroesophageal reflux and chronic obstructive pulmonary disease Some patients report difficulty becoming accustomed to sleeping with the BiPAP mask on, this therapy can dramatically improve symptoms Address spiritual concerns Directly address a patient questions, spiritual concerns, worries, and fears Can request for pastoral care or psychologist input 7 Other measures such as sleep restriction, cognitive behavioral therapy and biofeedback with progressive muscle relaxation are implemented as outpatient therapies usually under the guidance of a specialist References: 1. Wilson JF. In the clinic. Insomnia Ann Intern Med. 2008 Jan 1;148(1):ITC13-1-ITC13-16. 2. UPMC Presbyterian Shadyside, Pharmacy & Therapeutics Committee Drug Use and Disease State Management Program: Therapeutic Approaches to Acute Insomnia in Hospitalized Patients. 3. M Miller; R Arnold. Fast Fast Fact and Concept #104: Non-pharmacological Therapy for Insomnia. End-of-Life/Palliative Education Resource Center (www.eperc.mcw.edu). Accessed April 15, 2013 Pharmacologic treatments for insomnia: Class BZDs Non-BZDs** Antidepressant Drug (Generic name) Temazepam Starting po dose 15-30 mg,Elderly:7.5 mg Onset of action T max T1/2 Glucuronidation* Comments 30 min-1 hr 1.4 hrs 3-18 hrs Y Daytime sedation, anterograde amnesia, falls, rebound insomnia are found with all. rebound insomnia was not reported in studies of Non BZDs. Agitation, disorientation, headache have been reported with Non-BZDs. Zolpidem Is also associated with complex sleep behaviors (sleep driving, sleep eating) but may occur more with concomitant alcohol and antidepressants Not FDA approved. Is an automatic substitution for diphenhydramine for use in insomnia in elderly Lorazepam 1 mg Elderly:0.5 mg 30 min 0.5-3 hrs 12 hrs Y Oxazepam 15 mg No Data 2-3 hrs 3-9 hrs Y Zolpidem 10 mg.Elderly: 5 mg No Data 1.6 hrs 2.5 hrs N Zaleplon 10 mg Elderly: 5 mg No Data 1 hr 1 hr N Eszopiclone 2-3 mg Elderly: 1-2 mg No Data 1 hr 6 hrs N Trazodone 25-100 mg No Data 0.5-2 hrs 7.1 hrs N BZDs: Benzodiazepines, Non-BZDs: Non-Benzodiazepines *Only intermediate half life benzodiazepines are recommended for pharmacologic treatment of insomnia. Those with non-oxidative (glucuronidation) metabolism are preferred in the elderly. Oxidation for all except Zaleplon is via the cytochrome P450 pathway **UPMC preferred Other sedating antidepressants such as Tricyclics, Mirtazapine are not recommended for the treatment of pure insomnia without underlying depression because of higher incidence of anticholinergic and cardiac conduction side effects. For Restless Legs Syndrome, start Pergolide at a dose of 0.05 mg and increase to 0.2-0.5 mg taken in divided doses before bedtime). Side effects of pergolide include abdominal pain, nasal stuffiness, nightmares, and recurrence of symptoms earlier in the day. Other dopamine agonists such as bromocriptine, pramipexole, and ropinirole can also be used. If poorly tolerated, benzodiazepine agents, opiates or gabapentin may be used. 8 Nausea and Vomiting: Treatment Mechanism-based therapy involves the following steps: 1. A complete history and physical including oropharyngeal, abdominal, rectal and neurological exams 2. Consider labs: BUN/Cr, Na, LFT’s, amylase/lipase, Ca, drug levels 3. Consider imaging: flat plate of the abdomen to assess for constipation, Abdominal CT to evaluate for obstruction, Head CT/MRI 4. Determine which receptors are mediating the symptoms (see below) 5. Choose an antiemetic to block the implicated receptors (see next page) Pathophysiology of nausea and vomiting. Nausea and vomiting are triggered by activation of one of four main pathways: 1. Chemoreceptor Trigger Zone (CTZ): Main receptors: D2, 5HT3, NK1 2. Cortex: Main receptors are in the vomiting center. 3. Vestibular apparatus: Main receptors: Ach, H1 4. Peripheral pathways: Mediates nausea from triggering of GI/visceral chemoreceptors (local toxins) and mechanoreceptors (stretch). Enterochromaffin cells release 5HT3 when damaged (ie by chemotherapy or radiation) which activates local 5HT3 receptors. These four pathways send signals to the vomiting center (main receptors: H1, Ach, 5HT2) which triggers nausea and vomiting when thresholds are reached. If nausea is persistent, severe or refractory: • Schedule antiemetics around the clock, not PRN • Choose second and third antiemetics which work on different receptors. • Consider Palliative Care consult for second and third line therapies IN ADDITION TO USING ANTIEMETICS, ALWAYS TREAT ANY REVERSIBLE CAUSES (medications, anxiety, constipation, hypercalcemia, thrush, increased ICP, GERD, pain) ALWAYS EVALUATE FOR CONSTIPATION AND PERFORM A RECTAL EXAM Avoid use of promethazine because of adverse effects including sedation and respiratory depression Avoid benzodiazepines unless the nausea is from anxiety because they can sedate the patient and increase risk of aspiration For nausea associated with vomiting, give antiemetics via the IV route until symptoms are controlled Evaluate for clinical signs of bowel obstruction (persistent nausea briefly relieved by vomiting, abdominal pain, distended abdomen, obstipation) If bowel obstruction, consider surgery and/or GI consults for possible surgical repair or venting PEG tube Consider palliative care consult for medical management of bowel obstruction. References: Wood GJ, Shega JW, Lynch B, Von Roenn JH. Management of intractable nausea and vomiting in patients at the end of life “I was feeling nauseous all of the time…nothing was working.” JAMA. 2007;298(10): 1196-1207. Receptors: D2: Dopamine type 2 receptor, 5HT3: 5-hydroxytryptamine type 3 receptor, 5HT2: 5-hydroxytryptamine type 2 receptor, Achm: muscarinic acetylcholine receptor, H1: histamine type 1 receptor, NK1: Neurokinin type 1 receptor 9 Nausea and Vomiting: Treatment Drug (Generic Name) Receptor activity Common Clinical Indications Dosage/Route Cost Comments/ Side Effects Haloperidol D2 Opioid Induced N/V 0.5-4 mg PO or SQ or IV Q6h $ IV has less EPS compared to PO Metoclopramide Peripheral D2 Impaired GI motility Opioid Induced N/V 5-20 mg PO or SQ or IV AC and HS $ EPS, esophageal spasm,and colic in GI tract obstruction Prochlorperazine D2 Opioid Induced N/V N/V of unknown etiology 5-10 mg PO or IV every 6 h or 25mg PR Q6h $ EPS and sedation Scopolamine Ach, H1 Motion induced N/V 1.5 mg Transdermal patch every 3 d $ Dry mouth, blurred vision, ileus, urinary retention, and confusion Ondansetron 5HT 3 Chemotherapy or radiation induced N/V 4-8 mg PO as a pill or dissolvable tablet or IV every 4-8 h $$ Headache, fatigue, and constipation Dexamethasone Decrease ICP N/V related to Increased ICP 4-8 mg QAM or BID, PO (as pill or liquid) and IV $ Agitation, Insomnia, Hyperglycemia N/V: Nausea/Vomiting 10 Constipation and Bowel Protocol Medication Osmotic laxatives Onset of action Usual starting dosage Site and Mechanism of Action Lactulose 24-48 hr 15-30 ml q12-24 hr Polyethylene Glycol 48-96 hr 17g (1tbsp) powder in 8oz water q24 hr GI tract; osmotic effect Sorbitol 24-48 hr 15-30 ml q12-24 hr, max 150 ml/d Colon; delivers osmotically active molecules to the colon Magnesium citrate 30 min-3 hr 120-240 ml x1; 10 oz q24 hr Small and large bowel; attracts and retains water in the bowel lumen Magnesium hydroxide (MOM) 30 min-3 hr 30 ml q12-24h Colon; osmotic effect & increased peristalsis Bisacodyl 6-10 hr 5-15 mg x1 Colon; stimulates peristalsis Bisacodyl (PR) 15 min-1 hr 10 mg x1 Colon; stimulates peristalsis Senna 6-10 hr 2 tabs qhs Colon; stimulate myenteric plexus, alters water and electrolyte secretion 24-72 hr 100 mg q12-24 hr Small and large bowel; detergent activity; softens feces Colon; osmotic effect Saline Laxatives* Stimulant laxatives Surface laxatives Docusate Bulk laxatives alone are not useful in the treatment of opiate induced constipation *Avoid use of MOM and related products (including sodium phosphate enema products) in patients with renal dysfunction because of risk of hyperphosphatemia Reference: Reuben DB, Herr KA, Pacala JT, et al. Geriatrics at Your Fingertips 2009, 11th edition. New York: The American Geriatrics Society; 2009 11 Constipation and Bowel Protocol (page2) BOWEL REGIMEN: With few exceptions, all patients on opioid therapy need an individualized bowel regimen. When and effective regimen is found it must be continued for the duration of the opioid therapy. If a patient has not been on a bowel regimen, the step 1 regimen should be started. If there is no response in 24 hours, move to the next step. At any given time, if there has been no bowel movement in four or more days, a sodium phosphate or mineral oil enema should be administered. If this is not effective, a high colonic tap water enema should be administered. Be aware of the possibility of bowel obstruction or fecal impaction. A digital rectal exam should be performed prior to starting a bowel regimen and if no BM for 4 days. Other drugs that can exacerbate constipation: anticholinergics (tricyclic antidepressants, scopolamine, oxybutinin, promethazine, diphenhydramine), lithium, verapamil, bismuth, iron, aluminium, calcium salts. Opiod Antagonists to treat refractory constipation: Methylnaltrexone (MNTX) is a quaternary amine which does not cross the blood brain barrier to cause reversal of opioid analgesia or withdrawal. Use of oral naloxone for constipation has been associated with these effects. MNTX is approved for use in patients who have been on a steady opioid regimen for 2 weeks and laxative regimen for 3 days. Greater than 50% of patients will have a bowel movement within 4 hours of being given the dose by subcutaneous injection. In general, it is recommended that oral and rectal laxative regimens should have been tried, prior to utilizing MNTX. Pts with fecal ostomy bags and PD catheters were excluded from the studies. There is a dosing order set in the EMR. 12 Delirium: Diagnosis DSM-IV criteria for delirium include four components: A. Acute onset, over hours to days. B. Behavioral disturbance, marked by a reduced clarity in the patient’s awareness of the environment, with impaired ability to focus, sustain, or shift attention. The patient may be agitated, irritable, and emotionally labile, OR drowsy, quiet, and withdrawn. C. Consciousness level fluctuates over the course of the day. D. Different from dementia, delirium cannot be accounted for by a patient’s preexisting, established, or evolving dementia. Delirium is conceptualized as a reversible illness, except in the last 24–48 hours of life. 1. Delirium occurs in at least 25–50% of hospitalized cancer patients, and in a higher percentage of patients who are terminally ill. Delirium increases the risk of in-hospital and six-month mortality. 2. Differential diagnosis: D: Drugs (opioids, anticholinergics, sedatives, benzodiazepines, steroids, chemo- and immunotherapies, some antibiotics); E: Eyes and Ears (poor vision and hearing, isolation); L: Low flow states (hypoxia, MI, CHF, COPD, shock); I: Infections; R: Retention (urine/ stool), Restraints; I: Intracranial (CNS metastases, seizures, subdural, CVA, hypertensive encephalopathy); U: Under-hydration, Under-nutrition, Under-sleep; M: Metabolic disorders (sodium, glucose, thyroid, hepatic, deficiencies of vitamin B12, folate, niacin, and thiamine) and Toxic (lead, manganese, mercury, alcohol). 3. Routinely screen for delirium, and monitor delirious patients frequently. Confusion Assessment Method (CAM) ICU for the Diagnosis of Delirium Diagnosis positive with 1 and 2, plus 3 or 4 Feature 1. Acute onset and fluctuating course AND 2.Inattention PLUS 3. Disorganized thinking >2 errors OR 4. Altered level of consciousness Assessment Ask family or friends of patient Patient is easily distracted. Abnormal Digit Span: Inability to repeat a series of five digits (start with reading aloud a string of two random digits, then increase) and Vigilance A: At least two errors (read aloud in neutral normal tone a list of 10 letters with four A’s. Patient taps when A is read). Rambling or irrelevant conversation, unclear or illogical flow of ideas, or topic switching, or ask patient’s family. Ask: 1) Can a rock float? 2) Are there fish in the sea? 3) Is one pound more than two pounds? 4) Do you use a hammer to pound a nail? 5) Command say to patient, “Hold up this many fingers.” (Examiner holds two fingers in front of patient.) Next, do the same thing with the other hand (not repeating holding up the number of fingers). Hyper-alert, drowsy, stuporous, or unarousable 13 Delirium: Diagnosis The scale is completed based on information collected from each item over an 8 hour shift or the previous 24 hours. Obvious manifestation of an item = 1 point No manifestation of an item or no assessment possible = 0 point The Intensive Care Delirium Screening Checklist (ICDSC) Patient evaluation Altered Level of consciousness Day 1 Day 2 Day 3 Day 4 Day 5 If A or B do not complete patient evaluation for the period Inattention Disorientation Hallucinations-delusion-psychosis Psychomotor agitation or retardation Inappropriate speech or mood Sleep/wake cycle disturbance Symptom fluctuation Total Score Level of consciousness: A: no response No score B: response to intense and repeated stimulation (loud voice and pain) No score C: Response to mild or moderate stimulation 1 D: normal wakefulness 1 E: exaggerated response to normal stimulation 1 Inattention: Difficulty in following a conversation or instructions Disorientation: Any obvious mistake in time, place, person Hallucinations, delusion or psychosis: Overt clinical manifestation of hallucination or behavior related to hallucination or delusion Psychomotor agitation or retardation: Hyperactivity requiring restraints or drugs, clinically noticeable psychomotor slowing Inappropriate speech or mood: Disorganized or incoherent or inappropriate speech. Inappropriate display of emotion related to events of situation Sleep/wake cycle disturbance: Sleeping <4 hours or waking frequently at night (not initiated by staff or loud environment), sleeping during most of the day Symptom fluctuation: Fluctuation of any item over 24 hours Reference: See www.icudelirium.org for more information 14 Delirium: Treatment Rule out other medical causes of delirium. Review medications, and discontinue or decrease anticholinergic and/or benzodiazepine doses. Check for drugdrug interactions. Rotate opioids, reduce doses by 25% if possible, and avoid meperidine. Benzodiazepines are NOT effective in treating delirium, may worsen delirium, and should be used cautiously only as adjunct therapy with neuroleptics when relief of agitation is required. Neuroleptics are used for treatment of delirium. Haloperidol is the standard neuroleptic for treatment of delirium. Risperidone, olanzapine, and quetiapine are atypical neuroleptics, generally with fewer side effects. All neuroleptics can cause QT prolongation. Supportive care to prevent and reduce delirium includes frequent orientation (well-lit rooms, caregivers, calendars, clocks, communication), therapeutic activities (patient mobilization 3x/day when possible), non-pharmacologic sleep aids (see page 12), treatment of hearing and vision problems, treatment of incontinence, and volume repletion. Confusion increases the risk of falls. Pay attention to patient safety. Constant supervision (sitter) may be more beneficial than restraints or sedation. 15 Table 2: Drugs used for treatment of delirium in the hospital setting Generic name (Common brand name) Starting dose Dosing interval Max q24h dose Haloperidol (Haldol®) 0.5-1 mg (2 mg in ICU*) 0.5-1 hour for 20 mg urgent symptoms. Otherwise Q6H or Q8H Formulations EPS Anticholinergic Sedation Comments** 0.5, 1, 2, 5, 10 mg tablets. Available as oral solution and as an injectable product. +++ + ++ IV has less EPS compared to PO.*** (continued) Delirium: Treatment Generic name (Common brand name) Risperidone (Risperdal®) Starting dose Dosing interval Max q24h dose Formulations EPS Anticholinergic Sedation Comments** 0.25-1 mg 6 mg + + Caution with renal failure. 2.5-10 mg + +++ ++ Debilitated or elderly: 2.5 mg. IM: Q2H Quetiapine (Seroquel®) 12.5- 50 mg BID 800 mg 0.25, 0.5, 1, 2, 3, 4 mg tablets. Available as ODT (not for 0.25) 2.5, 5, 7.5, 10, 15, 20 mg tablets. Available as ODT (5, 10,15 & 20 mg) and IM injection 25, 50, 100, 200, 300, 400 mg tablets ++ Olanzapine (Zyprexa®) BID or up to Q6H PRN DAILY + ++ +++ Patients with hypoactive delirium, >70years CNS malignancy may not respond well. Start DAILY at 4pm for sundowning† and then time subsequent, additional doses based on symptoms. Aripiprazole (Abilify®) 5-15 mg Q AM 30 mg 2, 5, 10. 15, 20, 30 mg. Available as IM and oral solution. Available as ODT (10 & 15 mg) ++ + ++ 20 mg Useful for hypoactive delirium. Can cause insomnia if given at night Abbreviations: EPS: extrapyramidal symptoms; IM: intramuscular; IV: intravenous; ODT: oral disintegrating tablet; SQ: subcutaneous. Definition: †Sundowning: Onset of confusion in the elderly that typically begins in the evening *Refer to the UPMC Presbyterian Shadyside “Acute Agitation Management” order set. ** The FDA has determined that the use of antipsychotic medications in the treatment of behavioral disorders in elderly patients with dementia is associated with increased mortality. This risk appears to be highest during the first two weeks of use. *** Use IV haloperidol with caution in patients with prolonged QT interval. Increased risk of arrhythmia and sudden death exists with high IV doses. 16 Depression: Screening Tools and Treatment A shorter screening test for depression is to ask: Spiritual Distress Screen—A Quick Screen 1. Are you feeling either depressed or hopeless most of the time over the last 2 weeks? 1. Ask “Are you at peace?” 2. Have you found little brings you pleasure or joy over the last 2 weeks? From: R Arnold. Fast Fact and Concept #146: Screening for Depression in Palliative Care. End-of-Life/Palliative Education Resource Center (www.eperc.mcw.edu). 2005 Some select antidepressants are listed in the table next page: 2. If the answer is no, ask the patient if he/she would like to see a chaplain. Source: Archives of Internal Med 2006:166:101-5. 17 Commonly used antidepressants: dosing, formulations Category Generic (Common Brand Name) Starting PO dose (depression)* Dosing interval Therapeutic dose/day range* SSRIs Citalopram (Celexa®) 10-20 mg DAILY 10-60 mg Y 10, 20, 40 (tablets) 10 mg/5 mL (solution) Escitalopram (Lexapro®) 5-10 mg DAILY 10-20 mg N 5,10, 20 (tablets) 5 mg/5 mL (solution) Sertraline (Zoloft®) 25-50 mg DAILY 50-200 mg Y 25, 50, 100 (tablets) 100 mg/5 mL (solution) Venlafaxine (Effexor®) Venlafaxine XR (Effexor XR®) 75 mg/day divided BID-TID 150-375 mg Y 25, 37.5, 50, 75, 100 (tablets) 37.5-75 mg DAILY 75-225 mg N 37.5, 75, 150 (capsules) Duloxetine (Cymbalta®) Methylphenidate (Ritalin®) 20 mg BID 30-60 mg N 2.5-5 mg BID 8a,12p 5-40 mg (for depression) Y 20, 30, 60 (delayed-released capsules) 5, 10, 20 (tablets) SNRIs Stimulants Generic (Y/N) Formulations (mg) Abbreviations: CR, SR, XL, XR: sustained-release products SSRIs: Serotonic Specific Reuptake Inhibitors, SNRIs: Serotonin Norepinephrine Reuptake Inhibitors Others: Use the following w/caution in renally impaired patients: all SNRIs, all formulations of buproprion and mirtazapine Use the following w/caution in hepatically impaired patients: All SSRIs, methylphenidate, all SNRIs and bupropion *The therapeutic dose/day range varies from the minimum efficacious dose up to the maximum tolerated or daily recommended amounts. Maximum daily doses are dependent upon indication for use and should only be used as a guide. Initial doses should be low in elderly patients and increased gradually. Doses of up to 300 mg of venlafaxine XR have been used in practice, but are not FDA-approved. The doses for methylphenidate can be higher than 20mg but are generally not recommended. 18 Commonly used antidepressants: costs, side effects, comments Drug (Common brand name) Citalopram (Celexa®) Escitalopram (Lexapro®) Sertraline (Zoloft®) Venlafaxine (Effexor®) Venlafaxine XR (Effexor® XR) Cost per day* <$ Anticholinergic Insomnia GI Distress Comments** + + ++ Mild to moderately activating, few drug interactions. $ + +++ ++ t1/2 similar to Sertraline and Citalopram $ -- + +++ Moderately activating. $$ + +++ +++ $$$$ + +++ ++ Duloxetine (Cymbalta®) $$$$ ++ ++ ++ Methylphenidate (Ritalin®)*** <$ -- +++ + Dual serotonin/norepinephrine action at doses of 150-225mg which is effective in neuropathic pain and is mildly activating. On switching from the venlafaxine XR to venlafaxine, the shorter half life of venlafaxine requires frequent dosing to reach the same dose of venlafaxine XR. Use with caution in patients with hypertension. FDA-approved for diabetic neuropathy and off-label use for urinary incontinence. Do not use in patients with liver dysfunction. Use caution in patients with seizure disorder. Energizing, may increase appetite. Abbreviations: ODT: oral disintegrating tablet; t1/2 : half-life. *Cost per day of a typical daily dose was calculated based on generic products when available. Cost data was extrapolated from www.drugstore.com. **Activating antidepressants tend to cause insomnia. ***Not FDA-approved for treatment of depression. Differences in arrythmogenicity are not clinically relevant among these groups. 19 Treatment of Dyspnea and Pain at the End of Life 1. The following guidelines are for “comfort measures” patients ONLY. See CPOE CMO order sets. • “Titrate to comfort” medication orders are not acceptable. Parameters for drug dosing and titration must be included on all written and electronic care sets. 2. Opioid naive patient (all doses are for morphine): • Loading dose: 2–5 mg IV push. • If distress not relieved in 15 minutes after initial loading dose, give bolus equal the loading dose increased by 50 percent. If severe distress persists repeat the dose every 15 minutes until comfortable. • For increased pain/distress give extra bolus dose/s equal to the last given bolus dose every 30 minutes as needed. • If using more than 2 bolus doses over 6-hour period, consider starting a continuous infusion. To calculate the continuous infusion rate divide the total dose over last 6 hours by 6. 3. Non-naive patients: • For patients who have been taking opioid pain medications within last 24 hours calculate the equianalgesic parenteral dose of morphine for the last 24 hrs (see page 4 for opioid equivalencies). • Divide the total 24 hour IV morphine dose by 24 to determine initial hourly infusion rate (mg/hour, IV). Start continuous infusion at this rate. • If patient in pain/distress use loading dose = hourly infusion rate. • If distress not relieved in 15 minutes after initial loading dose or the patient in increased pain/distress, administer the loading dose increased by 50 percent and repeat every 15 minutes until comfortable. • If using more than two bolus doses over 6-hour period, determine new continuous infusion rate by recalculating total dose given over last 6 hours and dividing it by 6. 20 Oral Secretions at the End of Life As the level of consciousness decreases in the dying process, patients lose their ability to swallow and clear oral secretions. As air moves over the secretions, the resulting turbulence produces noisy ventilation with each breath, described as gurgling or rattling noises. Death rattle is a good predictor of near death; one study indicated the median time from the onset of death rattle to death was 16 hours. Drug Non-pharmacological treatments: Position the patient on their side or in a semi-prone position to facilitate postural drainage. Reassure family about noise; can compare to snoring. While there are no evidence-based guidelines, the standard of care is to use muscarinic receptor blockers (anti-cholinergic drugs). (Trade Name) Route Starting Dose Onset Scopolamine Transdermal 1 (~1 mg/3 days) 12 hrs. hyoscyamine sulfate Levsin Drops, Tabs (oral) 0.125 mg 30 min. glycopyrrolate Robinul Pills (oral) 1 mg 30 min. glycopyrrolate Robinul Injection (SC, IV) 0.2 mg 1 min. atropine Atropine Injection 0.1 mg 1 min. atropine multiple Sublingual* 1 gtt (1%) 30 min hyoscyamine hydrochloride *Use atropine ophthalmic drops. Tertiary amines which cross the blood-brain barrier (all but glycopyrrolate) cause CNS toxicity (sedation, delirium). Source: K Bickel; R Arnold. Fast Fact and Concept #109: Death Rattle and Oral Secretions, 2nd Edition. End-of-Life/Palliative Education Resource Center (www.eperc.mcw.edu) 2003. 21 UPMC Palliative Care and Pain Treatment Resources (area code 412) Inpatient Supportive and Palliative Care Services PUH/MUH Supportive & Palliative Care Service Shadyside Supportive & Palliative Care Service Magee Womens Hospital of UPMC Supportive and Palliative Care Service Children’s Hospital of Pittsburgh of UPMC Supportive Care Program VA Palliative Care Program 647-7243, pager: 8511 647-7243, pager: 8513 647-7243, pager: 8510 692-3234 Inpatient and oncology: 688-6000 Ext. 816178; or pager - 645-2345 Geriatric palliative care: pager - 958-0215 Inpatient Medical Ethics Services PUH/MUH Medical Ethics Shadyside Medical Ethics 647-7243, pager: 2881 263-8347 Pain Treatment Services PUH/MUH Chronic Pain Service Shadyside Chronic Pain Service PUH/MUH Acute Interventional Perioperative Pain Service (AIPPS) Shadyside Acute Interventional Perioperative Pain Service (AIPPS) 647-4991 665-8030, after hours call 665-8031 647-7243, pager: 7246 (PAIN) 692-2333 Outpatient Services UPMC Hillman Cancer Center’s Cancer Pain and Supportive Care Program UPMC Heart and Vascular Institute’s Advanced Heart Failure Clinic Magee Women’s Cancer Center Magee Gynecologic Cancer Program Benedum Geriatric Center Supportive Care Clinic Renal Supportive Care Clinic Magee - Chronic non malignant/spine/muscular skeletal pain (outpatient) UPMC Presbyterian Pain Medicine (outpatient) St. Margaret Pain Medicine (outpatient) and Chronic Pain Service 692-4724 647-6000 641-4530 641-5411 or 641-5566 692-4200 802-3043 901-2891 692-2234 784-5119 (outpatient) or 784-4000 (Hospital Operator) Family Hospice and Palliative Care 572-8800 22 Indications for Palliative Care Referral: •Pain in patients with life-limiting illness •Management of other symptoms such as nausea, vomiting, shortness of breath, delirium •Negotiating goals of treatment or end-of-life decision making •Family support for a patient with a life-limiting illness •Psychological or spiritual counseling for patients and their families •Discharge planning and interface with local hospices •Bereavement services in the event of death •Outpatient palliative care follow-up Questions or comments regarding this information, contact Robert Arnold, MD ([email protected]), 692-4834, pager 2322. This information provided by the UPMC Supportive and Palliative Care Program is merely in the form of recommendations and does not replace the service of a physician. Author: Mamta Bhatnagar, MD with Lisa Podgurski, MD; Susan Skledar, RPh, MPH; Peg Verrico, RPh; and Robert Arnold, MD. This pain card was made possible with the assistance of Kimberly L. Gottschalk, MBA and the generous support of the UPMC Palliative and Supportive Institute. Produced in cooperation with the University of Pittsburgh. UMC90239-0413 VERSION 9.0 PAIN CARD 23
© Copyright 2024